Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Oral BG-12 (dimethyl fumarate) for relapsing-remitting multiple sclerosis: a review of DEFINE and CONFIRM Evaluation of: Gold R, Kappos L, Arnold D, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;
Neurological Dysfunction in Early Maturity of a Model for Niemann-Pick C1 Carrier Status.
Individual Assessment of Brain Tissue Changes in MS and the Effect of Focal Lesions on Short-Term Focal Atrophy Development in MS: A Voxel-Guided Morphometry Study.
Ethyl-eicosapentaenoic acid ameliorates the clinical course of experimental allergic encephalomyelitis induced in dark agouti rats.
Metaboreflex activity in multiple sclerosis patients.
Functional neuroimaging may quantify spinal cord demyelinating disease.
Intrinsic third ventricular craniopharyngioma: A case report.
The substrate of increased cortical FA in MS: A 7T post-mortem MRI and histopathology study.
Quantitative MRI of the spinal cord and brain in adrenomyeloneuropathy: in vivo assessment of structural changes.
[Differntial diagnosis of neuromyelitis optica].
The therapeutic potential of cannabinoids for movement disorders.
Increased incidence of multiple sclerosis in systemic sclerosis: A nationwide cohort study.
Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations.
Neuropathology of JC virus infection in progressive multifocal leukoencephalopathy in remission.
Imaging gray matter with concomitant null point imaging from the phase sensitive inversion recovery sequence.
Inverse and Direct Cancer Comorbidity in People with Central Nervous System Disorders: A Meta-Analysis of Cancer Incidence in 577,013 Participants of 50 Observational Studies.
Rad51 Activates Polyomavirus JC Early Transcription.
Robotic gait rehabilitation and substitution devices in neurological disorders: where are we now?
A home-based comprehensive care model in patients with Multiple Sclerosis: A study pre-protocol.
Tuftsin-driven experimental autoimmune encephalomyelitis recovery requires neuropilin-1.
Motor unit number index (MUNIX): Is it relevant in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP)?
Genome-wide association studies in neurology.
Neuron-macrophage crosstalk in the intestine: a "microglia" perspective.
Optimal detection of infratentorial lesions with a combined dual-echo MRI sequence: "PT2".
Thrombotic processes in multiple sclerosis as manifestation of innate immune activation.
Pages
« first
‹ previous
…
581
582
583
584
585
586
587
588
589
…
next ›
last »